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ABSTRACT
Lysyl oxidase-like 2 (LOXL2) is associated with invasiveness and metastasis in 
cancer. We analyzed the prognostic impact of LOXL2 in pancreatic cancer patients and 
investigated the role of LOXL2 in pancreatic cancer cell lines. Immunohistochemical 
analysis was performed in samples from 80 patients and showed LOXL2 expression 
in 81.2% of patients with pancreatic cancer. Regarding recurrence patterns, LOXL2-
positive tumors showed a significantly higher rate of distant recurrence. The 1-year 
and 3-year disease-free survival rates were 84.6% and 0.0%, respectively, for LOXL2-
negative patients, and 27.8 % and 0.0 %, respectively, for LOXL2-positive patients. 
On univariate analysis, combined resection of major vessels, depth of invasion, tumor 
stage, and LOXL2- positive status were significant factors for poor prognosis. After 
identification of LOXL2 expression in pancreatic cancer cell lines, LOXL2-silenced 
and LOXL2-overexpressed cell lines were used to perform transwell invasion and 
transendothelial migration assays.
In vitro studies indicated that LOXL2 silencing in MIA PaCa-2 and PANC-1 cells 
induced a mesenchymal–epithelial transition (MET)-like process associated with 
decreased invasive and migratory properties. LOXL2 overexpression in AsPC-1 and 
BxPC-3 cells enhanced the epithelial-mesenchymal transition (EMT)-like process and 
increased migratory and invasive activity. These clinical and preclinical data confirm 
that higher LOXL2 expression is associated with the invasiveness of pancreatic cancer 
cells and the low survival rate of pancreatic cancer patients. Our results suggest the 
clinical value of LOXL2 as a therapeutic target in pancreatic cancer.
INTRODUCTION
Pancreatic cancer is one of the most aggressive 
and lethal malignancies. Although pancreatic cancer is 
a relatively rare disease, it is the fourth leading cause of 
cancer-related mortality in Korea. Despite the availability 
of several treatment modalities, the 5-year survival rate 
is reported to be lower than 5% [1]. This poor clinical 
prognosis is mainly associated with early local invasion 
and a high incidence of recurrence, both of which are 
characteristic of the disease. To improve the outcomes of 
pancreatic cancer, the underlying metastatic mechanisms 
should be better understood.
LOX-like 2 (LOXL2) is a member of the lysyl 
oxidase (LOX) family, which contains five homologs, 
LOX and four LOX-like proteins (LOXL1-4), which are 
secreted, copper-dependent amine oxidases [2–5]. LOXL2 
catalyzes the covalent cross-linking of collagen and 
elastin component side chains through its lysyl oxidase 
activity, thereby stabilizing the proteins in the extracellular 
matrix (ECM). Additionally, several studies have shown 
that LOXL2 down-regulates E-cadherin expression and 
promotes epithelial-mesenchymal transition (EMT) 
[6–8]. Due to these mechanisms, LOXL2 is associated 
with aggressive cancer characteristics and poor patient 
prognosis. Several studies have reported that LOXL2 is 
associated with poor prognosis in cancer patients [9–13], 
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and that overexpression of LOXL2 promotes invasion 
activity among cancer cells [10-12, 14, 15]. LOXL2 is 
up-regulated in human pancreatic cancer, and might be 
correlated with the regulation of different transcription 
factors associated with invasion and metastasis [16]. 
The activity of lysyl oxidase (e.g., LOX and LOXL2) 
also, correlates with oncogenic stress response and 
tumorigenesis in pancreatic ductal adenocarcinoma [17]. 
However, there is a paucity of clinical evidence regarding 
the role of LOXL2 and its functions in pancreatic cancer.
In this study, we aimed to confirm the role of 
LOXL2 in the increased invasiveness of pancreatic cancer 
cells and to evaluate the clinical impact of LOXL2 in 
patients with pancreatic cancer. To accomplish this, we 
examined pancreatic cancer tissue for LOXL2 expression 
via immunohistochemical (IHC) staining and evaluated 
the prognostic significance of LOXL2 for pancreatic 
cancer patients. Moreover, we performed in vitro studies 
that showed an association between an aggressive cancer 
prognosis and LOXL2 expression.
RESULTS
Clinicopathologic characteristics
The study involved patients of a mean age of 63.3 
(± 9.7) years including 39 men and 41 women. Of the 80 
patients, eight underwent pancreaticoduodenectomy, 41 
underwent pylorus-preserving pancreaticoduodenectomy, 
26 underwent distal pancreatectomy with splenectomy 
and five underwent total pancreatectomy. According to 
the 7th AJCC classification, one patient was stage IA, 
four were stage IB, 22 were stage IIA, 50 were stage IIB, 
and three were stage III. All patients received adjuvant 
chemotherapy with six cycles of gemcitabine every 4 
weeks. Each chemotherapy cycle consisted of three 
weekly infusions of gemcitabine 1000mg/m2 administered 
via intravenous infusion over a 30-min period, followed 
by a 1-week pause.
Analysis of clinicopathologic features and 
LOXL2 status
Among the 80 patients, 65 (81.2%) were positive for 
LOXL2. The clinicopathologic features and LOXL2 status 
of patients in the study group are summarized in Table 
1. There was no statistical difference in clinicopathologic 
characteristics according to LOXL2 status.
Patterns of recurrence according to LOXL2 
status
Among the 80 patients, 67 (83.8%) had tumor 
recurrence confirmed via pathologic or radiologic 
examination. Regarding recurrence patterns, LOXL2-
positive tumors showed a significantly higher rate of 
distant recurrence (Table 2).
Prognostic impact of LOXL2 status
In these 80 patients, the 1- and 3- year disease-free 
survival (DFS) rates were 38.8 % and 0.0%, respectively. 
On univariate and multivariate analyses, tumor stage and 
LOXL2-positive status were identified as independent 
prognostic factors for DFS (Table 3, 4). The 1 and 3-year 
DFS rates were 84.6% and 0.0%, respectively, for patients 
with LOXL2-negative tumors and 27.8% and 0.0%, 
respectively, for patients with LOXL2-positive tumors 
(Figure 1).
The overall 3-and 5-year survival rates were 20.0% 
and 6.1%, respectively. On univariate analysis, combined 
resection of major vessels, depth of invasion, tumor stage 
and LOXL2-positive status were significant factors for 
poor prognosis. In the multivariate analysis, combined 
resection of major vessels was identified as an independent 
prognostic factor for overall survival.
LOXL2 expression and invasiveness in 
pancreatic cancer cell lines
Expression of LOXL2 was analyzed in a series 
of pancreatic cancer cell lines: MIA PaCa-2, PANC-1, 
AsPC-1, and BxPC-3. LOXL2 was detected in MIA PaCa-
2 and PANC-1 yet, not in AsPC-1, and BxPC-3 (Figure 
2A). LOXL2 expression correlated with the expression 
of Snail and L1CAM and was inversely proportional to 
the expression of epithelial cell markers such as CDH1 
(Figure 2A). An analysis of transwell invasion (Figure 
2B) and transendothelial migration (Figure 2C) indicated 
that expressions of these genes were not correlated with 
the properties of migration and invasiveness of each 
pancreatic cancer cell, suggesting that each pancreatic 
cancer cell has LOXL2- independent mechanisms to 
control the expression of LOXL2, Snail, CDH1, and 
L1CAM, which is related to EMT and invasiveness.
The effects of LOXL2 expression on invasiveness
We generated stable pancreatic carcinoma cells 
in which LOXL2 was silenced by siLOXL2, (MIA 
PaCa-2 and PANC-1) or ectopically expressed by pc3.1- 
LOXL2 (AsPC-1 and BxPC-3). Selected clones from 
MIA-PaCa-siLOXL2 and PANC1-siLOXL2 showed 
significantly reduced LOXL2 protein (Figure 3A and 
3B) and transcript levels (Figure 3C and 3D). These 
cells exhibited significant changes in the expression of 
molecules related to invasiveness and EMT. LOXL2 
silencing induced significant correlation between reduced 
Snail expression and increased CDH1 expression in 
PANC-1-siLOXL2 cells, though, not in MIA PaCa-2 
cells. Considering that CDH1 protein was not detected in 
MIA PaCa-2 due to its transcriptional silencing (Figure 
3A and 3B) and the low levels of CDH1 expression (MIA 
PaCa-2) and downregulation (MIA PaCa-2-siLOXL2), 
LOXL2 silencing and reduced Snail might not affect the 
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Table 1: Patients characteristics based on LOXL2 status
LOXL2 negative (N=15) LOXL2 positive (N=65) p-value
Age (mean ± SD), yr 63.1 ± 10.9 63.3 ± 9.4 0.961
Sex 0.858
 Male 7 32
 Female 8 33
Operative Procedure 0.186
 PD/PPPD 7 42
 Distal pancreatectomy 8 18
 Total pancreatectomy 0 5
Combine resection 0.551
 No 13 52
 Yes 2 13
Tumor size (mean ± SD), cm 3.5 ± 1.6 3.4 ± 1.8 0.782
Histologic grade 0.138
 Well differentiation 2 12
 Moderate differentiation 8 45
 Poor differentiation 5 8
Depth of invasion 0.713
 T1 0 1
 T2 2 5
 T3 13 56
 T4 0 3
Lymph node metastasis 0.881
 Negative 5 23
 Positive 10 42
Perineural Invasion 0.671
 No 4 21
 Yes 11 44
Lymphovascular invasion 0.775
 No 7 33
 Yes 8 32
Tumor Stage 0.461
 IA 0 1
 IB 1 3
 IIA 4 18
 IIB 10 40
 III 0 3
Table 2: Patterns of recurrence according to LOXL2 status
LOXL2 negative LOXL2 positive P-value
Recurrence patterns 0.044
 Local recurrence 8 17
 Distant recurrence 5 37
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Table 3: Univariate prognostic factors of disease free survival rate in pancreatic cancer
1-yr DFS 3-yr DFS p-value
Age (yr) 0.956
 ≥ 60 40.4 0.0
 < 60 35.0 0.0
Sex 0.152
 Male 51.5 0.0
 Female 26.5 0.0
Operative Procedure 0.190
 PD/PPPD 26.2 0.0
 Distal pancreatectomy 60.0 0.0
 Total pancreatectomy 60.0 0.0
Combine resection 0.876
 No 37.5 0.0
 Yes 45.5 0.0
Tumor size (cm) 0.892
 ≥ 2cm 39.3 0.0
 < 2cm 40.0 0.0
Histologic grade 0.373
 Well differentiation 54.5 0.0
 mod differentiation 31.8 0.0
 poor differentiation 50.0 0.0
Depth of invasion 0.717
 T1/T2 40.0 0.0
 T3/T4 38.7 0.0
Lymph node metastasis 0.240
 Negative 52.2 0.0
 Positive 31.8 0.0
Perineural Invasion 0.318
 No 34.8 0.0
 Yes 40.9 0.0
Lymphovascular invasion 0.4111
 No 33.3 0.0
 Yes 44.1 0.0
Tumor Stage 0.033
 IA/IB 33.3 0.0
 IIA 61.1 0.0
 IIB 32.6 0.0
 III 0.0 0.0
LOXL2 status 0.002
 Negative 84.6 0.0
 Positive 27.8 0.0
Table 4: Univariate analysis of disease free survival rate in pancreatic cancer
Variables P-values Odds ratio
Confidence interval (95%)
Lower Upper
LOXL2 positive 0.002 2.810 1.474 5.357
Tumor stage 0.047 1.623 1.007 2.618
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re-expression of CDH1. The expressions of vimentin and 
N-cadherin, which are related to EMT, were not affected 
significantly by LOXL2, as demonstrated by slight up-
regulation of these proteins on densitometric analysis of 
NIH images (Figure 3B). Downregulation of phospho-
SRC and phospho-FAK was detected on Western blot 
analyses and reduced expressions of Snail and L1CAM 
were detected at both mRNA and protein levels (Figure 
3A-3D). Contrary to a previous report by Rückert et al. 
[16], our experimental set for LOXL2 knockdown by 
siLOXL2 influenced the cell morphology, resulting in 
cells that were less spindle-shaped, less atypical, and 
smaller, though only in MIA-PaCa-2-siLOXL2; however, 
silencing or ectopic overexpression of LOXL2 did not 
affect the morphology of the other cell lines (Figure 3E). 
Importantly, silencing of LOXL2 resulted in a marked 
decrease in motility and the invasiveness capacity of MIA 
PaCa-2 (p < 0.001) and PANC-1 cells, as determined from 
transwell invasion and transendothelial migration assays, 
respectively (Figure 4A and 5).
We also observed a significant influence of ectopic 
overexpression of LOXL2 in AsPC-1-LOXL2 and BxPC-
3-LOXL2 cells. Decreased expression of CDH1 and 
increasing phospho-FAK / phospho-SRC were observed 
in AsPC-1-LOXL2 and BxPC-3-LOXL2 cells (Figure 
3A-3D). Upregulation of L1CAM was detected only in 
BxPC-3-LOXL2. Upreulation of Snail expression was 
also detected in both AsPC1-LOXL2 and BxPC3-LOXL2. 
(Figure 3A-3D). Conversely, LOXL2 overe-xpression 
enhanced the migration potential of BxPC-3-LOXL2 (p < 
0.001), but not AsPC-1-LOXL2. (Figure 4B).
DISCUSSION
LOXL2, a member of the LOX family, is responsible 
for the stabilization of collagen and elastin fibers in ECM 
through covalent oxidative deamination. Tissue fibrosis 
is associated with cancer progression through direct 
promotion of cellular transformation and metastasis [18]. 
Lu et al. reported that the increased collagen cross-linking 
in mouse mammary stroma induced by LOXL2 activity 
is associated with ECM stiffness and tumor invasion and 
progression [14]. These studies are in agreement with the 
notion that tumor fibrosis increases the invasive behavior 
of tumors by activating LOXL2 signals and suggest that 
LOXL2 is involved in cell adhesion, cell migration and 
invasion, and EMT transformation [6, 9].
Figure 1: Disease free survival rates according to LOXL2 status.
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Although many studies have shown that increased 
LOXL2 expression is associated with lymph node 
metastasis, lymphatic invasion, and advanced tumor stage 
[10, 11], IHC staining of LOXL2 was not associated with 
clinicopathologic variables in this study. This disparity 
might be explained by the unusual characteristics of 
pancreatic cancer, which exhibits a high expression of 
EMT properties even in its early stage. In fact, the ratio 
of LOXL2 positivity in early-stage pancreatic cancer was 
higher than that in breast cancer, renal cell carcinoma, and 
stomach cancer [10, 11, 19]. This disparity necessitates 
further investigation of LOXL2 in pancreatic cancer. 
Moreover, investigation of recurrence patterns showed 
that LOXL2 expression was significantly associated 
Figure 2: LOXL2 expression and properties of migration and invasiveness were analyzed in pancreatic cancer cell 
lines. A. on Western blot analysis, LOXL2 was only detected in MIA PaCa-2 and PANC-1. Exp.30m, Snail was analyzed after 30 minutes 
of exposure. Each cell showed independent properties of migration and invasiveness (B. transwell invasion assay; C. transendothelial 
migration assay).
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Figure 3: Analysis of LOXL2 expression in pancreatic cancer cell lines with LOXL2-silencing and LOXL2-
overexpression. A. Western analysis and B. densitometric analysis using NIH image; LOXL2 silencing (siLOXL2) reduced LOXL2, 
Snail, p-FAK, p-SRC and L1CAM, and increased CDH1 in MIA PaCa-2 and PANC-1. LOXL2 overexpression (LOXL2) showed increased 
LOXL2, Snail, p-FAK, p-SRC and L1CAM, and reduced CDH1 in AsPC-1 and BxPC-3. C. RT-PCR analysis and D. quantitation of RT 
PCR; LOXL2 silencing has an effect on the reduction of LOXL2, Snail, and L1CAM, and on the increase of CDH1. LOXL2 overexpression 
has an effect on the increase of LOXL2, Snail, and L1CAM, and on the reduction of CDH1. E. MIA-PaCa-2-siLOXL2 cells exhibited a 
more epithelial phenotype than si-control. siCon, siRNA control using siRNA scramble; siLOXL2, siRNA for LOXL2; vc, vector(pc3.1) 
control; LOXL2, pc3.1-LOXL2; L.E, Snail was exposed for more 3 min more than other proteins.
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Figure 4: Effect of LOXL2 on pancreatic cancer cell invasion based on transwell invasion assay. LOXL2-silencing A. and 
LOXL2-overexpression B. have an effect on the capacity of motility and invasiveness of pancreatic cancer cell lines.
Figure 5: Effect of LOXL2 on pancreatic cancer cell invasion based on transendothelial migration assay. LOXL2-
silencing has an effect on the capacity of motility and invasiveness of MIA PaCa-2 and PANC-1.
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with distant metastasis, including the liver and lung, as 
described in a previous report [10]. This result suggests 
that LOXL2 expression might be associated with the 
EMT activity of pancreatic cancer. On univariate and 
multivariate analyses of DFS, the prognosis of LOXL2-
positive patients was significantly worse than that of 
LOXL2-negative patients. These findings suggest that 
LOXL2 over-expression might be a poor prognostic 
factor in pancreatic cancer, based on evidence that LOXL2 
expression in pancreatic cancer cells might contribute to 
metastasis in a clinical setting, and further suggest that 
inhibition of LOXL2 might provide a survival benefit to 
patients with pancreatic cancer.
To identify whether the clinical significance of 
LOXL2 expression in pancreas cancer patients is associated 
with metastasis and EMT properties, we conducted an in 
vitro study of LOXL2 in pancreatic cancer cells.
In previous studies, intracellular functions of 
LOXL2 have been postulated relating to the promotion of 
EMT and the invasiveness of cancer cells. LOXL2 induces 
EMT by stabilizing Snail, a suppressor of CDH1 [8, 20, 
21] in carcinoma progression [6]. LOXL2 even controls 
CDH1 by regulating H3K4me3 deamination [22], and 
LOXL2-E47 EMT factor plays a role in the repression of 
CDH1 in early metastasis colonization of breast cancer 
cells [23]. Additionally, positive modulation of the FAK 
and SRC pathways by LOXL2 has been reported, which 
can contribute to cell migratory behavior [8, 11, 20, 24, 
25]. More recently, Holly E. Baker et al. showed that 
LOXL2 activated fibroblasts via integrin-mediated FAK 
activation in tumor cell invasion and metastasis [26]. 
The expression of L1CAM, an adhesion molecule, is 
associated with poor prognosis and spontaneous metastasis 
of cancer cells to the lung [27–29]. Additionally, EMT and 
NF-κB activation is associated with the up-regulation of 
L1CAM, which enhances cell invasion and motility and 
tumor metastasis formation [30]. Gregg et al. suggested 
that hypoxia inducible factor dependent on expression of 
L1CAM and LOX family members (LOX, LOXL2, and 
LOXL4), which promotes cancer cell extravasation and 
metastatic niche formation in breast cancer cells [31].
We found that LOXL2 plays an integral role in the 
promotion of EMT and the invasiveness of pancreatic 
cancer cells. Our in vitro study indicated that LOXL2 
activates EMT-like processes in pancreatic cell lines that 
are associated with invasive and migratory properties. 
Moreover, LOXL2 contributes positively to the activation 
of FAK/SRC and influences the expressions of CDH1, 
Snail and L1CAM, which are all related to EMT and the 
invasiveness of pancreatic tumor cells [12, 13, 15, 29, 32-
35]. The present results support the notion that LOXL2 
is involved in the maintenance of the mesenchymal 
phenotype in pancreatic cancer cells and are consistent 
with previous results in other studies [25, 36–39].
It has been reported that LOXL2 is one of the most 
highly and specifically upregulated genes in pancreatic 
cancer, compared to normal pancreatic tissues [40]. 
Proteomic profiling detected the gene product of LOXL2 
in pancreatic cancer cells as well as in the secretions 
of pancreatic cancers [41, 42]. In addition, LOXL2 
has been associated with pancreatic cancer pathology 
and tumorigenicity. For instance, inhibition of LOXL2 
has been shown to result in the reduced viability of 
pancreatic cancer cells and their increased sensitivity to 
chemotherapy [16]. Moreover, in light of the promising 
role of LOXL2 in promoting the activation of EMT-related 
molecules that increase the aggressiveness of pancreatic 
cancer, it is noteworthy that LOXL2 was prominently 
expressed in the majority of pancreatic cancer tissues in 
our study.
Our finding has clinical importance in that provides 
a novel potential therapeutic target for pancreatic cancer. 
Based on experimental evidence, LOXL2 has previously 
been proposed as a therapeutic target in the treatment 
of pancreatic cancer [23, 43, 44]. The current targeting 
strategy for LOXL2 focuses on inhibiting its enzymatic 
activity. LOXL2 seems to be effectively targeted 
at the protein level either through the use of small-
molecule inhibitors that may act both intracellularly and 
extracellularly, or through the use of antibodies [44]. 
Therefore, our data also support a therapeutic approach 
in which intracellular LOXL2 expression could be an 
effective target molecule for the improved survival of 
pancreatic cancer patients.
Although there were limitations to our study, 
including the retrospective study design and small sample 
size, our findings provide preclinical and clinical evidence 
that the contribution of LOXL2 enzymatic activity to 
metastasis in an experimental setting can be translated into 
poor survival outcomes in patients with pancreatic cancer.
In conclusion, results from an IHC analysis of 
tumors demonstrated that LOXL2 is an independent 
marker for metastatic disease and death in patients 
with pancreatic cancer. Additionally, our in vitro study 
demonstrated that LOXL2 expression promotes EMT and 
the invasiveness of pancreatic cancer cell lines, a finding 
compatible with the results of previous in vitro studies. 
These findings suggest that LOXL2 could potentially be 
a valuable target for the improvement of survival rates in 
patients with pancreatic cancer.
MATERIALS AND METHODS
Patients
Between June 2002 and December 2012, 84 patients 
underwent radical curative resection for pancreatic cancer 
at Gangnam Severance Hospital, Yonsei University 
College of Medicine, Seoul, Korea. Among these patients, 
four were excluded due to poorly preserved tissue samples, 
incomplete clinicopathologic data, or loss to follow-up. As 
a result 80 patients who had undergone curative resection 
were retrospectively reviewed. All patients were followed 
up for more than 6 months and the mean duration of 
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follow-up was 33.2 ± 9.7 months. Patients were followed 
every 3 months during the first 12 months, and then every 
6 months beyond the first year. This study was approved 
by the Institutional Review Board of Gangnam Severance 
Hospital, Yonsei University, Seoul, Korea (3-2014-0153).
Immunohistochemical (IHC) Staining
Serial sections (5 µm) of each block were adhered to 
poly-L-lysine covered slides and incubated at 62°C for 60 
minutes. After the elimination of paraffin with xylene and 
staged ethyl alcohol dehydration, the sections were heated 
in a microwave containing a 10-mM citrate buffer (pH 
6.0) solution for 15 minutes. The primary antibody against 
LOXL2 (Abcam, Cambridge, UK) was used at a 1:1,000 
dilution according to the manufacturer’s instructions. 
The procedure has been described in detail elsewhere 
[21]. Normal pancreas tissue present within the block and 
appropriate control tissues were used as positive controls.
IHC staining for LOXL2 was categorized as 
negative, “1+”,“2+”,or “3+” in high-power fields (200x 
magnification) according to the intensity of cytoplasmic 
staining (Figure 6). LOXL2-positive status was assigned 
for scores “2+”and “3+”. The interpretation of IHC was 
evaluated by two pathologists who had no information 
regarding the clinical outcomes.
Cell culture
Pancreatic cancer cell lines MIA PaCa-2, PANC-1, 
AsPC-1, and BxPC-3 were purchased from the American 
Type Culture Collection (ATCC; Manassas, VA, USA) and 
grown in accordance with ATCC recommendations. MIA 
PaCa-2, PANC-1 and AsPC-1 were poor differentiation 
cell type, and BxPC3 is moderate to poor differentiation 
cell type [45]. MIA PaCa-2 and PANC-1 were 
characterized as LOXL2-positive whereas AsPC-1 and 
BxPC3 were characterized as LOXL2-negative pancreatic 
cancer cells.
Construction of LOXL2-siRNA and LOXL2 
expression vector
For knockdown of LOXL2 mRNA, 
we used the following sequences: siLOXL2, 
5'-CAGUCUAUUAUAGUCACAU-3'. As a negative 
control, we used siRNA targeting green fluorescence 
protein: 5'-GGUGUGCUGUUUGGAGGUCTT-3'. The 
human LOXL2 cDNA clone was provided from the Korea 
Human Gene Bank, Medical Genomics Research Center, 
KRIBB, Korea. The LOXL2 clone was inserted into the 
mammalian expression vector pcDNA3.1(+) (Invitrogen, 
San Diego, CA) by PCR using the following primers: (F: 
5'- CTA GCT AGC ATG GAG AGG CCT CTG-3' and 
R: 5'- CGC GGA TCC TTA CTG CGG GGA CAG -3'). 
The construct was verified by sequencing. Cells were 
transfected with LOXL2-siRNA or pc3.1-LOXL2 at 50 % 
confluence using the transfection reagent Oligofectamine 
(Invitrogen, Carlsbad, CA, USA), according to the 
manufacturer’s instructions.
Reverse transcription polymerase chain reaction 
(RT-PCR) and quantitative RT-PCR
RNA was extracted using the Trizol reagent 
(Invitrogen, Carlsbad, CA), and cDNA was synthesized 
using the MMLV enzyme (Invitrogen). PCR was 
performed at 95oC for 10 min and in 25 cycles at 95oC 
for 15 s, 62oC for 30 s, and 72oC for 30 s on a GeneAmp 
PCR System 9700 (Applied Biosystems, Foster City, 
CA, USA). Each PCR product was analyzed in 20% 
agarose gel. Quantitative RT-PCR was performed 
on LightCycler®480 Real-Time PCR System (Roche 
Diagnostics, Mannheim, Germany) using SYBR 
Green I Matermix (Roche Diagnostics, Mannheim, 
Germany). Primers used for RT-PCR were LOXL2 
(F: 5'-AACGAGGCGACCCTTGCAGC-3' and R: 
5'- GGGTGCGCTTGCGGTAGGTT-3'); Snail, (F: 
5'-AATCGGAAGCCTAACTACAGCGAG-3' and R: 
5'-CTTTCCCACTGTCCTCATCTGACA-3'); CDH1, 
(F: 5'-GACGCGGACGATGATGTGAAC-3'and R: 
5'-TGTACGTGGTGGGATTGAAGA-3'); L1CAM, 
(F: 5'-GCCACCTGTCATCACGGAAC-3' and R: 
5'-GTCCAGCGGAACTGCACTTC-3') and GAPDH, 
(F: 5'-CGGGAAGCTTGTGATCAATGG-3' and R: 
5'-GGCAGTGATGGCATGGACTG-3'). The experiments 
were performed in triplicate and normalized to GAPDH.
Western blot analysis
Cell lysates were prepared in RIPA buffer (Sigma, St 
Louis, MO, USA) supplemented with protease inhibitors. 
Protein samples were separated by 10% sodium dodecyl 
sulfate–polyacrylamide gel electrophoresis and transferred 
onto nitrocellulose membranes. The membranes were 
blocked and probed with primary antibody against LOXL2 
(Origene; Rockville, MD, USA), Snail (Cell Signaling; 
Danvers, MA, USA), pFAK and FAK (Santa Cruz, CA, 
USA), pSRC (Millipore, Billerica, MA, USA), SRC 
(Santa Cruz, CA, USA), CDH1 (BD Biosciences; Sparks, 
MD), L1CAM (Novus Biologicals, Littleton, CO, USA), 
N-cadherin (Invitrogen, CA, USA), Vimentin (Dako, 
Glostrup, Denmark) and β-actin (Sigma, St Louis, MO, 
USA). The intensity of the western blotss was quantified 
by densitometric scanning with ImageJ (NIH) and 
normalized to β-actin.
Tranwell invasion assay
The invasive potential of pancreatic cancer 
cells was assessed in vitro in matrigel-coated invasion 
chambers (Corning; NY, USA) in accordance with the 
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Figure 6: Immunohistochemical analysis of LOXL2. LOXL2 expression was evaluated at a high-power field (x200 
magnification). A. One positive for LOXL2. B. Two positives for LOXL2. C. Three positives for LOXL2.
A
B
C
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manufacturer’s instructions. Briefly, cells in the log 
growth phase were serum starved for 24 h prior to seeding, 
detached by brief trypsinization and resuspended in 
medium containing the appropriate treatment. The matrigel 
invasion inserts were rehydrated and prepared as described 
in the manufacturer’s instructions. Cells in serum-free 
medium at a density of 1 X 105 cells/ml/well were placed 
on the top of matrigel-coated polycarbonate filters (8 µm 
pore size) suspended in a membrane invasion culture 
system chamber; the chamber underneath the membrane 
contained complete medium. The cells were incubated 
in a CO2 incubator at 37
oC for 5 h, after which the non-
invasive cells were removed from the upper surface of the 
membrane and the invasive cells on the undersurface of 
the membrane were fixed and stained with hematoxylin–
eosin (H&E; Sigma-Aldrich). These experiments were 
performed in triplicate at least three times. The invading 
cells were counted under a fluorescence microscope in five 
random high-power fields.
Transendothelial migration assay
HUVEs and EGMTM-2 media (Lonza, Walkersville, 
MD, USA) was purchased. HUVECs (3×104 in 200 µl of 
EGM-2 medium) were seeded onto 0.1% gelatin-coated 
inserts in the transwell chamber (8-µm pore size and 6.5-
mm diameter) and allowed to form a monolayer for 48 h. 
The endothelial culture medium was removed from each 
insert and CFSE-labeled cancer cells (1×105 cells in 200µl 
of serum-free medium) were added on top of the HUVEC 
monolayer. Cancer cell culture medium containing 10% 
FBS was added to the lower chamber. After incubation for 
48 or 72 h, non-migratory cells were wiped off with cotton 
swabs and the membrane was washed with PBS. Finally, 
the membranes were removed from the transwell insert, 
mounted onto slides and observed under a fluorescence 
microscope at ×10 magnification.
Statistical analysis
All clinicopathologic variables except age and 
tumor size were used as categorical variables. Differences 
in continuous variables between the two groups were 
evaluated using Student’s t-test, and differences in 
categorical variables were evaluated by the chi-square 
test. The Kaplan-Meier method was used to calculate 
and display survival curves, and the log-rank test was 
performed to determine differences among all groups. 
Overall survival was defined as the time interval between 
the date of surgery and the date of death from cancer or the 
last follow-up. Recurrence-free survival was defined as the 
time interval between the date of surgery and the date of 
recurrence or last follow-up. The Cox proportional hazards 
regression method was used to determine independent 
prognostic factors. A P-value of less than 0.05 was 
considered to be statistically significant.
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